Clinical Research

Novartis Pharma AG

Address
Lichtstrasse 35

Sponsor Overview

assignment
226
sponsored trials
science
284
molecules
location_city
1672
research centres
public
26
countries
person_search
4295
investigators

Specializations

Oncology and Hematologic Malignancies

Novartis Pharma AG funds a broad oncology portfolio spanning solid tumours and blood cancers, with particular interest in breast cancer, prostate cancer, lung cancer, colorectal cancer, ovarian cancer, melanoma, and glioblastoma. Its studies also extend across lymphoma, leukemia, multiple myeloma, and other advanced malignancies.

  • Advanced solid tumours
  • Breast and prostate cancers
  • Lymphoma and leukemia
  • Glioblastoma and melanoma

The trial portfolio includes cancers defined by molecular features such as KRAS G12C, PIK3CA, EGFR, BRAF, IDH1, and PSMA expression, alongside radioligand and immunotherapy-related research in metastatic disease.

Immunology, Inflammation, and Autoimmune Disease

The sponsor supports research in immune-mediated disorders including systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Sjögren’s syndrome, and systemic sclerosis. It also studies immune thrombocytopenia, warm autoimmune hemolytic anemia, and vasculitis.

  • Systemic autoimmune diseases
  • Inflammatory arthritides
  • Immune cytopenias
  • Autoinflammatory syndromes

Additional work covers hidradenitis suppurativa, chronic spontaneous urticaria, atopic dermatitis, food allergy, and autoinflammatory diseases linked to rare genetic immune dysregulation.

Cardiovascular and Metabolic Disorders

Novartis invests in studies of atherosclerotic cardiovascular disease, acute coronary syndrome, atrial fibrillation, heart failure, calcific aortic valve stenosis, and cardiovascular risk reduction. The portfolio also includes lipid-related conditions such as elevated lipoprotein(a), familial hypercholesterolemia, and hypercholesterolemia.

  • Coronary and structural heart disease
  • Arrhythmia and heart failure
  • Lipid disorders
  • Atherosclerotic risk reduction

Related research includes pulmonary arterial hypertension, non-obstructive coronary artery disease, and inflammatory cardiovascular mechanisms involving CHIP.

Nephrology, Complement-Mediated, and Renal Disease

The sponsor maintains active interest in chronic kidney disease, acute kidney injury, IgA nephropathy, atypical hemolytic uremic syndrome, complement 3 glomerulopathy, and idiopathic immune-complex membranoproliferative glomerulonephritis. Its renal portfolio also includes lupus nephritis and sepsis-associated acute kidney injury.

  • Glomerular disease
  • Complement-mediated disorders
  • Kidney injury and chronic kidney disease
  • Immune-mediated renal disease

Research extends to paroxysmal nocturnal hemoglobinuria and other complement-driven conditions that intersect with renal and hematologic complications.

Neurology, Ophthalmology, and Rare Genetic Disease

The sponsor funds clinical research in multiple sclerosis, myasthenia gravis, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis, and schizophrenia. It also studies spinal muscular atrophy, progressive supranuclear palsy, refractory seizures, and Alzheimer’s disease.

  • Demyelinating disease
  • Neuromuscular disorders
  • Neurodegenerative disease
  • Rare inherited conditions

Additional research includes age-related macular degeneration, retinitis pigmentosa, PIK3CA-related overgrowth spectrum, lymphatic malformations, and other rare disorders with genetic and developmental origins.

Sponsored Trials

Trial Name Country Status
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long-term treatment-free follow-up period for up to an additional 3 years.Germany GermanyItaly ItalyPoland PolandSpain SpainThe Netherlands The NetherlandsUnknown
A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.Bulgaria BulgariaCzechia CzechiaFrance FranceGermany GermanyHungary HungaryItaly ItalyPoland PolandSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsNot Recruiting
A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a)Germany GermanyNot Recruiting
A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis SuppurativaAustria AustriaBelgium BelgiumBulgaria BulgariaCroatia CroatiaCzechia CzechiaGreece GreeceHungary HungaryItaly ItalyLithuania LithuaniaPoland PolandPortugal PortugalSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsNot Recruiting
A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)Czechia CzechiaDenmark DenmarkFrance FranceGermany GermanyGreece GreeceItaly ItalyPoland PolandSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsRecruiting
A multicenter, randomized, double-blind, placebo-controlled, Phase II platform study to assess the efficacy and safety of investigational compound(s) in patients with moderate to severe atopic dermatitisCzechia CzechiaFrance FranceGermany GermanyHungary HungaryItaly ItalyPoland PolandSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsRecruiting
A multicenter, randomized, participant- and investigator -blinded, placebo-controlled, phase 2a study to assess the efficacy, safety and tolerability of GIA632 in adult participants with moderate to severe atopic dermatitisBulgaria BulgariaCzechia CzechiaFrance FranceGermany GermanyPoland PolandNot Yet Recruiting
A multicenter, single arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who have Hb≥10 g/dL in response to anti-C5 antibody and switch to iptacopanFrance FranceGermany GermanyItaly ItalySpain SpainNot Recruiting
A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GXV813 in Hospitalized Adults with SchizophreniaBulgaria BulgariaRecruiting
A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of Secukinumab 300 mg Subcutaneous in Adults with Moderate to Severe Rotator Cuff TendinopathyBulgaria BulgariaCzechia CzechiaDenmark DenmarkFrance FrancePortugal PortugalSlovakia SlovakiaNot Recruiting
1–10 of 226
1 / 23

Data & Insights

science
Molecule Portfolio
Compounds under investigation
55
Exclusive Molecules
out of 284 total (19% not shared with other sponsors)

This sponsor works with 284 molecules, of which 55 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
64%
Return partnership rate
1067 of 1672 sites collaborated multiple times

This sponsor has worked with 1672 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Neoplasms88 trials
    853 other sponsors
  • 2.
    Immune System Diseases48 trials
    322 other sponsors
  • 3.
    Cardiovascular Diseases23 trials
    359 other sponsors
  • 4.
    Nervous System Diseases23 trials
    449 other sponsors
  • 5.
    Musculoskeletal Diseases10 trials
    238 other sponsors
  • 6.
    Skin and Connective Tissue Diseases9 trials
    247 other sponsors
  • 7.
    Hemic and Lymphatic Diseases8 trials
    249 other sponsors
  • 8.
    Congenital, Hereditary, and Neonatal Diseases and Abnormalities7 trials
    165 other sponsors
  • 9.
    Respiratory Tract Diseases5 trials
    277 other sponsors
  • 10.
    Eye Diseases3 trials
    138 other sponsors
  • 11.
    Not possible to specify2 trials
    220 other sponsors
  • 12.
    Digestive System Diseases1 trial
    280 other sponsors
  • 13.
    Female Urogenital Diseases and Pregnancy Complications1 trial
    142 other sponsors
  • 14.
    Immune system processes1 trial
    65 other sponsors
  • 15.
    Male Urogenital Diseases1 trial
    111 other sponsors
  • 16.
    Mental Disorders1 trial
    150 other sponsors
  • 17.
    Metabolism1 trial
    38 other sponsors
  • 18.
    Parasitic Diseases1 trial
    9 other sponsors

Partnered Research Centres

1672 centres
location_city
assignment2
"GAMMED" IZABELA CHUCHROWSKA
Address
ul. Lelechowska 5, 02-351 Warsaw
Learn morearrow_forward
location_city
assignment5
1 NZOZ Pro Cordis Sopockie Centrum Badan Kardiologicznych Pawel Miekus
Address
ul. Partyzantow 39/64, 81-423 Gdynia
Learn morearrow_forward
location_city
assignment23
401 General Military Hospital Of Athens
Address
Panagioti Kanellopoulou Av 1, 115 25 Athens
Learn morearrow_forward
location_city
assignment2
A & P Kft.
Address
Fo Utca 170, 7694 Hosszuheteny
Learn morearrow_forward
location_city
assignment22
A.O. Krankenhaus St. Josef Braunau GmbH
Address
Ringstraße 60, 5280 Braunau am Inn
Learn morearrow_forward
location_city
assignment103
A.O.U. Policlinico G. Martino Di Messina
Address
Via Consolare Valeria N 1, 98124 Messina
Learn morearrow_forward
Page 1 of 279

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Novartis Pharma AG.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.